Virginia Nagy, MD
Family Medicine · Lake Ozark, MONPI 1396783445
Payments from drug & device makers
Across 181 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$504
- Novo Nordisk$413
- AbbVie$276
- Pfizer$251
- Dexcom, Inc.$239
- AstraZeneca$149
- plus $1K from 23 others
What the payments were for
- Consulting fees$211%
- Food & beverage$2,86799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $504 |
| Novo Nordisk | 24 | $413 |
| AbbVie(2 entities) | 16 | $276 |
| Pfizer | 19 | $251 |
| Dexcom, Inc. | 10 | $239 |
| AstraZeneca | 10 | $149 |
| Merck | 8 | $132 |
| GSK | 9 | $131 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Novartis | 6 | $99 |
| Boehringer Ingelheim | 5 | $76 |
| Lilly USA, LLC | 5 | $67 |
| Johnson & Johnson | 5 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Exact Sciences | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Mylan Specialty L.p. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Z-medica, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$2,887 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 116 | $154,859 |
| OzempicSemaglutide | 84 | $116,362 |
| MounjaroTirzepatide | 69 | $77,832 |
| EliquisApixaban | 57 | $65,949 |
| JardianceEmpagliflozin | 73 | $50,435 |
| XareltoRivaroxaban | 13 | $19,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,918 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $7,760 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 27 | $7,375 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,121 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,038 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $5,729 |
| Duloxetine Hcl | 67 | $4,979 |
| Levothyroxine Sodium | 613 | $4,894 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 204 | $4,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $67 | $232,691185 claims |
| Novo NordiskOzempic | $413 | $116,36284 claims |
| PfizerEliquis, Abrysvo | $251 | $69,59069 claims |
| Boehringer IngelheimJardiance | $76 | $50,43573 claims |
| Johnson & JohnsonXarelto | $61 | $19,24413 claims |
| GSKTrelegy Ellipta, Arexvy | $131 | $15,29339 claims |
| AstraZenecaSymbicort | $149 | $7,12128 claims |
| AbbVieSynthroid | $276 | $4,10173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Lake Ozark
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.